We still creates new interfaces and offers solutions for a variety of problems that are facing biotech, everyday around here at Yaohai*. To this point, we have an entire team dedicated to figuring out how these manufacturing methods can be drawn forward for what is arguably one of the most important therapeutic modalities for millions of serious diseases: mRNA therapies. We all know the utility of Design of Experiments (DoE) when we start developing mRNA medicine, faster, in better quality. This extends to, among others, cancer and genetic diseases, as previously mentioned. However, manufacturing of this medicine was complicated and time consuming. Here we would like to speed up the entire process as well, and guarantee a final product that is as good as it can be (as you have seen above) This can also become easier with DoE techniques.
One of the major applications of DoE in our SRM effort is to augment laboratory processing around mRNA manufacture. In vitro transcriptions(IVT): The transcription of RNA using DNA template guidance. So what we can do for IVT then, is you have different factors that cross with … so in the temperature of how long we let this reaction take place. It is quite possible to decipher what change works how by observing the impact such changes have on the final outcome. This gives us a hugely helpful window into how to make mRNA that is both safe and broadly applicable in many important therapeutics.
Additional help from DoE : I often use DoE many times to ensure the issues which you probably encounter during the IVT phase must resolve. Sure, some of the time something is bound to screw up — we got sent the wrong form of mRNA. That is where DoE becomes really interesting, we can dig deeper into these problems and try to get rid of them. The idea is that we can optimize the system more broadly and ensure we consistently produce good mRNA every time. So, you just adjust your practice to improve that and thus the quality of our mRNA on this side. And it produces more consistent, and more reliable results from our end.
Also, we will complement DoE with statistical analysis to further enhance our optimization of the IVT process. In other words, we analyze the data to reveal what parts of our process affect the quality of our mRNA. This is the data which we can correlate with some other aspects and it thing did everything influences to final answer. Now that we know that, we can work out how to streamline and boost our mRNA manufacturing capabilities to carry the best results. It has allowed us to work more efficiently and quickly.
Thank you very much, this is a great development of mRNA medicine by DoE. Our goal is to enhance the IVT step, and provide you with more original mRNAs even faster. And that would be beneficial for more patients in need of an effective treatment. As such, we strive everyday to develop a sharpened edge in navigating this ever-evolving landscape. Safely and securely for sure, but we want to be tops at this, it may well save lives.